Clinical Trial

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream 20 mg/g compared with cream vehicle in the treatment of adult participants with mild to severe palmoplantar pustulosis (PPP). Total study duration for each participants will be approximately 18 weeks, for an approximate total of 9 visits.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2025-06-02; most recent amendment 2026-07-20.
Status change: Not Yet Recruiting → Recruiting 2025-07-29
Trial Details
NCT Number NCT07013201
Lead Sponsor LEO Pharma
Conditions Palmoplantar Pustulosis
Enrollment 135 participants
Start Date 2025-09-11
Primary Completion 2026-12-14 (estimated)
Study Completion 2026-12-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-21